Abstract: Access to global public healthcare is impacted by many technical, economic, and social factors. It is widely recognized that the resources required to deliver and improve global public health are currently constrained. A powerful way to increase access is to lower the cost of products and services that have already proven to be effective. Currently, the cost of producing a wide range of pharmaceutical products is higher than it needs to be.
The worldwide opioid crisis has occasioned efforts to develop new opioids for both existing uses (pain control) as well as new indications (itch, addiction). We have focused on the discovery of compounds able to selectively activate one of the two main intracellular pathways associated with the kappa opioid receptor. This type of activity, called “functional selectivity” or “ligand bias”, has the potential to segregate many of the ultimate biological effects of therapeutic opioids.